Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1α-dependent Induction of Polo-Like Kinase 4

Abstract Centrosome amplification (CA) has been implicated in the progression of various cancer types. Although studies have shown that overexpression of PLK4 promotes CA, the effect of tumor microenvironment on polo-like kinase 4 (PLK4) regulation is understudied. The aim of this study was to examine the role of hypoxia in promoting CA via PLK4. We found that hypoxia induced CA via hypoxia-inducible factor-1α (HIF1α). We quantified the prevalence of CA in tumor cell lines and tissue sections from breast cancer, pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, and prostate cancer and found that CA was prevalent in cells with increased HIF1α levels under normoxic conditions. HIF1α levels were correlated with the extent of CA and PLK4 expression in clinical samples. We analyzed the correlation between PLK4 and HIF1A mRNA levels in The Cancer Genome Atlas (TCGA) datasets to evaluate the role of PLK4 and HIF1α in breast cancer and PDAC prognosis. High HIF1A and PLK4 levels in patients with breast cancer and PDAC were associated with poor overall survival. We confirmed PLK4 as a transcriptional target of HIF1α and demonstrated that in PLK4 knockdown cells, hypoxia-mimicking agents did not affect CA and expression of CA-associated proteins, underscoring the necessity of PLK4 in HIF1α-related CA. To further dissect the HIF1α-PLK4 interplay, we used HIF1α-deficient cells overexpressing PLK4 and showed a significant increase in CA compared with HIF1α-deficient cells harboring wild-type PLK4. These findings suggest that HIF1α induces CA by directly upregulating PLK4 and could help us risk-stratify patients and design new therapies for CA-rich cancers. Implications: Hypoxia drives CA in cancer cells by regulating expression of PLK4, uncovering a novel HIF1α/PLK4 axis.

[1]  K. Mittal,et al.  Spotlighting the hypoxia‐centrosome amplification axis , 2020, Medicinal research reviews.

[2]  Christopher C. Griffith,et al.  Hypoxia Induced Centrosome Amplification Underlies Aggressive Disease Course in HPV-Negative Oropharyngeal Squamous Cell Carcinoma , 2018 .

[3]  I. Prior,et al.  Targeting centrosome amplification, an Achilles' heel of cancer , 2019, Biochemical Society transactions.

[4]  Xin Wang,et al.  PLK4: a promising target for cancer therapy , 2019, Journal of Cancer Research and Clinical Oncology.

[5]  Z. Liao,et al.  High PLK4 expression promotes tumor progression and induces epithelial-mesenchymal transition by regulating the Wnt/β-catenin signaling pathway in colorectal cancer , 2018, International journal of oncology.

[6]  J. Pereira-Leal,et al.  Centrosome amplification arises before neoplasia and increases upon p53 loss in tumorigenesis , 2018, The Journal of cell biology.

[7]  André F. Vieira,et al.  Over-elongation of centrioles in cancer promotes centriole amplification and chromosome missegregation , 2018, Nature Communications.

[8]  E. Dmitrovsky,et al.  Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers , 2018, Proceedings of the National Academy of Sciences.

[9]  E. Nigg,et al.  Once and only once: mechanisms of centriole duplication and their deregulation in disease , 2018, Nature Reviews Molecular Cell Biology.

[10]  M. Burkard,et al.  Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma , 2018, Molecular Cancer Research.

[11]  S. Rajagopal,et al.  PLK4: a link between centriole biogenesis and cancer , 2018, Expert opinion on therapeutic targets.

[12]  Y. Padwad,et al.  HIF-1 in cancer therapy: two decade long story of a transcription factor , 2017, Acta oncologica.

[13]  R. Kaur,et al.  Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer , 2017, British Journal of Cancer.

[14]  P. Rida,et al.  Prognostic value of CA20, a score based on centrosome amplification-associated genes, in breast tumors , 2017, Scientific Reports.

[15]  S. Varambally,et al.  Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells , 2017, Scientific Reports.

[16]  G. Blandino,et al.  Che-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1α stabilization , 2017, Journal of experimental & clinical cancer research : CR.

[17]  Marjorie Fournier,et al.  KAT2-mediated PLK4 acetylation contributes to genomic stability by preserving centrosome number , 2016, Molecular & cellular oncology.

[18]  D. Hedley,et al.  Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts , 2016, Oncotarget.

[19]  V. Bautch,et al.  Tumor-Derived Factors and Reduced p53 Promote Endothelial Cell Centrosome Over-Duplication , 2016, PloS one.

[20]  Zhenhua Li,et al.  Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy , 2016, Journal of Cancer.

[21]  R. Kaur,et al.  A centrosome clustering protein, KIFC1, predicts aggressive disease course in serous ovarian adenocarcinomas , 2016, Journal of Ovarian Research.

[22]  M. Fischer,et al.  The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes , 2015, Nucleic acids research.

[23]  Xi Chen,et al.  EglN2 associates with the NRF1‐PGC1α complex and controls mitochondrial function in breast cancer , 2015, The EMBO journal.

[24]  Yongping Cui,et al.  Loss of KLF14 triggers centrosome amplification and tumorigenesis , 2015, Nature Communications.

[25]  S. Varambally,et al.  Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma , 2015, Cell cycle.

[26]  Ashley V. Kroll,et al.  Reversible centriole depletion with an inhibitor of Polo-like kinase 4 , 2015, Science.

[27]  R. Osan,et al.  Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers , 2015, Oncotarget.

[28]  D. Pellman,et al.  Causes and consequences of centrosome abnormalities in cancer , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[29]  C. Moreno,et al.  E2F Activators Signal and Maintain Centrosome Amplification in Breast Cancer Cells , 2014, Molecular and Cellular Biology.

[30]  J. Hudson,et al.  p53-Dependent and Cell Specific Epigenetic Regulation of the Polo-like kinases under Oxidative Stress , 2014, PloS one.

[31]  W. De,et al.  The role of Aurora A in hypoxia-inducible factor 1α-promoting malignant phenotypes of hepatocelluar carcinoma , 2013, Cell cycle.

[32]  Giuseppe Cicero,et al.  HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions , 2013, Breast Cancer Research and Treatment.

[33]  Crispin J. Miller,et al.  A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer , 2013, Clinical Cancer Research.

[34]  H. Saito,et al.  SAPK pathways and p53 cooperatively regulate PLK4 activity and centrosome integrity under stress , 2013, Nature Communications.

[35]  S. Duensing,et al.  CAND1 promotes PLK4-mediated centriole overduplication and is frequently disrupted in prostate cancer. , 2012, Neoplasia.

[36]  J. Chan.  A Clinical Overview of Centrosome Amplification in Human Cancers , 2011, International journal of biological sciences.

[37]  Jiannis Ragoussis,et al.  High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. , 2011, Blood.

[38]  S. Duensing,et al.  The HPV-16 E7 oncoprotein induces centriole multiplication through deregulation of Polo-like kinase 4 expression , 2011, Molecular Cancer.

[39]  M. Bornens,et al.  Polo-like kinase 4: the odd one out of the family , 2010, Cell Division.

[40]  A. Gulino,et al.  The Alternative TrkAIII Splice Variant Targets the Centrosome and Promotes Genetic Instability , 2009, Molecular and Cellular Biology.

[41]  T. Kietzmann,et al.  Transcriptional regulation of serine/threonine kinase-15 (STK15) expression by hypoxia and HIF-1. , 2008, Molecular biology of the cell.

[42]  L. Huang,et al.  Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. , 2008, Blood.

[43]  Y. Liu,et al.  Centriole overduplication through the concurrent formation of multiple daughter centrioles at single maternal templates , 2007, Oncogene.

[44]  J. Pouysségur,et al.  Harnessing the hypoxia-inducible factor in cancer and ischemic disease. , 2007, Biochemical pharmacology.

[45]  E. Nigg,et al.  Origins and consequences of centrosome aberrations in human cancers , 2006, International journal of cancer.

[46]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[47]  Christopher J. Wilkinson,et al.  The Polo kinase Plk4 functions in centriole duplication , 2005, Nature Cell Biology.

[48]  T. Lawrence,et al.  SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing. , 2005, Neoplasia.

[49]  Erich A. Nigg,et al.  Polo-like kinases and the orchestration of cell division , 2004, Nature Reviews Molecular Cell Biology.

[50]  W. Lingle,et al.  Centrosome amplification and the development of cancer , 2002, Oncogene.

[51]  K. Münger,et al.  Human papillomaviruses and centrosome duplication errors: modeling the origins of genomic instability , 2002, Oncogene.

[52]  Carol Reynolds,et al.  Centrosome amplification drives chromosomal instability in breast tumor development , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[53]  K. Münger,et al.  The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Holger Karas,et al.  TRANSFAC: a database on transcription factors and their DNA binding sites , 1996, Nucleic Acids Res..

[55]  H. Tilson,et al.  Neurotransmitter receptors in brain regions of acrylamide-treated rats. I: Effects of a single exposure to acrylamide , 1981, Pharmacology Biochemistry and Behavior.